| 9/21/2021 |
Antigen dominance hierarchies shape TCF1 + progenitor CD8 T cell phenotypes in tumors - PubMed |
National Institutes of Health |
... Boston, MA 02115, USA. 5 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Radiation Oncology , Massachusetts General Hospital, Boston, MA 02114, USA. 6 Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School ... |
| 9/21/2021 |
Appointments and advancements for Sept. 7, 2021 | 2021-09-07 | BioWorld |
BioWorld |
... and corporate strategy roles at Atara Biotherapeutics Inc.Insilico Medicine Hong Kong Ltd. , of Hong Kong, appointed Robert Spiegel acting chief medical officer. Following a fellowship at the National Institutes of Health in medical oncology , Spiegel was the director of developmental therapeutics at NYU Cancer Center. He also spent over 25 years at Schering-Plough (now Merck & Co. Inc.).Jubilant Biosys Ltd. , of Bangalore, India, named Giuliano Perfetti CEO. Prior ... |
| 9/20/2021 |
Optical Imaging Market worth $3.3 billion by 2026 – Exclusive Report by MarketsandMarkets™ |
express-press-release.net |
... USA, 2021-Sep-20 — /EPR Network/ — According to the new market research report “ Optical Imaging Market by Technique (OCT, NIRS, HSI, PAT) Product (Imaging System, Camera, Lens, Software) Therapeutic Area (Ophthalmology, Oncology , Dermatology), Application (Pathological, Intra-operative), End user (Research) – Global Forecast to 2026″, published by MarketsandMarkets™, the global Optical Imaging Market is projected to reach USD 3.3 billion by 2026 from USD 1.6 ... |
| 9/20/2021 |
Zacks Investment Research Upgrades GT Biopharma (OTCMKTS:GTBP) to Buy |
baseballnewssource.com |
Zacks Investment Research upgraded shares of GT Biopharma (OTCMKTS:GTBP) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. They currently have $8.50 target price on the stock. According to Zacks, “GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs ... |
| 9/20/2021 |
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC |
itbusinessnet.com |
... September 19, 2021 – Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.’s Libtayo® (cemiplimab) combination treatment were presented today during a late-breaking session at the European Society for Medical Oncology Virtual Congress 2021. The trial, which met its primary overall survival (OS) endpoint and all key secondary endpoints, assessed the investigational use of PD-1 inhibitor Libtayo in combination with a physician’s choice of ... |
| 9/20/2021 |
Hemato Oncology Testing Market worth USD 4.0 billion : Increasing Incidence of Hematologic Cancer |
PRSync |
Hemato Oncology Testing Market worth USD 4.0 billion : Increasing Incidence of Hematologic Cancer [MNM] - Monday, September 20, 2021. Submitted by [Ritika Tyagi] . According to the new market research report “ Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the ... |
| 9/20/2021 |
Global Cancer Biopsy Market Analysis Report 2021: Advent of Liquid Biopsy & Transition of Novel Oncology Diagnostics from Bench to Clinics - Forecast to 2027 |
Globe Newswire |
... high costs are currently bridged by tissue biopsies. This has made tissue biopsy a gold-standard procedure in the present diagnostic scenario. Liquid biopsies are expected to offer lucrative opportunities in the field of oncology-based personalized medicine and genomic data analysis. Recognizing the potential of these tests, the regulatory bodies are actively supporting the commercialization of these products and increasing the use of these assays in clinics. For instance ... |
| 9/20/2021 |
Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories |
Business Wire |
... Residential University Setting,” opened with a presentation from Hrusovsky, who shared a vision for advancing preventative medicine and precision health through early disease detection paradigms enabled by ultra-sensitive biomarker measurements in neurology, oncology and infectious disease, including COVID-19. Dr. Roback shared experiences of the Emory team navigating the challenges associated with establishing a rapid, high-throughput, accurate COVID-19 testing program to enable a safe, in-person ... |
| 9/20/2021 |
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 - Stocks News Feed |
stocksnewsfeed.com |
... the results of the final analysis are being presented during the Mini Oral Session – NETs and Endocrine Tumours at 5:30 p.m. CEST on Monday, September 20 at the 2021 European Society of Medical Oncology (ESMO) Congress (LBA67). At a median follow-up of 10.1 months, the significant improvement in PFS with CABOMETYX was maintained, with consistent benefit in subgroups based on prior treatment.“Given the urgent need for new ... |
| 9/20/2021 |
Oncology Information Systems Market 2021 Company Overview, Recent Developments and SWOT Analysis 2028 |
unlvrebelyell.com |
Oncology Information Systems Market 2021 Company Overview, Recent Developments and SWOT Analysis 2028 The Esticast Research published a Oncology Information Systems Market study report , which has all company profile the key companies and brands, and along with that the report also included a synopsis of market trends, definition, application, and classification. The forecast period 2021-2028 is anticipated to be great for the Oncology Information Systems market, which will be the ... |
| 9/20/2021 |
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors |
Globe Newswire |
Äì Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly ‚Äì BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus ... |
| 9/20/2021 |
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study |
Zacks |
... 2021).Data from the KRYSTAL–1 study also demonstrated that the therapy was well tolerated among the participants in both arms of the cohort. The data were presented at the European Society for Medical Oncology Congress (ESMO) 2021.Mirati has completed enrolment in a phase II potentially registration-enabling monotherapy cohort of adagrasib for treating patients with at least second-line non-small cell lung cancer (“NSCLC”) with KRAS ... |
| 9/20/2021 |
Immuno-oncology Therapy Market Research 2021 – Includes Historical, Forecast Data, Demand, Application, Price Trends, and Company Share By 2028 |
dailyresearchsheets.com |
Immuno-oncology Therapy Market Research 2021 – Includes Historical, Forecast Data, Demand, Application, Price Trends, and Company Share By 2028 This has brought along several changes in This report also covers the impact of COVID-19 on the global market. The rising technology in Immuno-oncology Therapy Market is also depicted in this research report. Factors that are boosting the growth of the market, and giving a positive push to ... |
| 9/20/2021 |
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors |
matinasbiopharma.com |
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors – Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform ... |
| 9/20/2021 |
Immuno-oncology Therapy Market Analysis by Size, Segment and Evolution Rate by Type and Application Forecast to 2027 |
themarketpublicist.com |
... in this report: Amgen AstraZeneca Bristol-Myers Squibb Eli-Lilly Roche GlaxoSmithKline Janssen Biotech Merck Novartis Pfizer Sanofi Spectrum Pharmaceuticals Takeda BioNTech SE Allogene Therapeutics IMAB-I-Mab Biopharma Co., Ltd. Arcus Biosciences Gritstone Oncology Autolus Therapeutics Rubius Therapeutics Global Immuno-oncology Therapy Market segmentation: Segment by Type Monoclonal Antibodies Immune Checkpoint Inhibitors Immune System Modulators Cancer Vaccines Segment by Application Hospitals Ambulatory Surgical Center Others Key highlights of this ... |
| 9/20/2021 |
Clay County professional licenses expiring in week ending Sept. 19 |
claycotimes.com |
... the numerous bills trying to cut back on red tape. Professional licenses expiring in Clay County in the week ending Sept. 19 Company Name License Type License Number Date of License Expiration Southeast Veterinary Oncology Veterinary Medicine CRS1828 09/19/2021 Southeast Veterinary Oncology Veterinary Medicine CRS1829 09/19/2021 ... |
| 9/20/2021 |
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer |
patientdaily.com |
Mirati Therapeutics, Inc. issued the following announcement on Sep. 9. Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant ... |
| 9/20/2021 |
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board - Stocks News Feed |
stocksnewsfeed.com |
... novel immunotherapies will help us maintain our leadership postion as we advance our platform for patients with blood cancers and solid tumors.”Dr. Park is Associate Attending Physician in the Division of Hematologic Oncology , Leukemia Service, a Director of Adult Acute Lymphoblastic Leukemia Program and the Acting Chief of Cellular Therapeutics Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Park received his medical degree ... |
| 9/20/2021 |
Disposable Cuvettes Market – Overview on Key Innovations 2027 |
tradersherald.com |
... Scientific Waters Corporation Agilent Technologies Bruker Corporation Danaher Corporation Segment by Regions North America Europe China Japan Southeast Asia India Segment by Type Reagents Instruments Kits Enzymes Segment by Application Diagnostics Drug Discovery & Development Oncology Immunology Others Each market player encompassed in the Disposable Cuvettes market study is assessed according to its market share, production footprint, current launches, agreements, ongoing R&D projects, and business tactics. In addition, the Disposable ... |
| 9/20/2021 |
Crwe World | Merit Medical Announces Positive Results in First-in-Human Study of WRAPSODY‚Ñ¢ Cell-Impermeable Endoprosthesis |
crweworld.com |
... SOUTH JORDAN, Utah, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology , critical care and endoscopy, announced today positive results from a prospective, observational, first-in-human study to evaluate the safety and effectiveness of the Merit WRAPSODY Endoprosthesis. The WRAPSODY Endoprosthesis is a self-expanding, cell ... |